Skip to main content
main-content

01.12.2017 | Study protocol | Ausgabe 1/2017 Open Access

Trials 1/2017

Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial

Zeitschrift:
Trials > Ausgabe 1/2017
Autoren:
Susan Chan, Victoria Cornelius, Tao Chen, Suzana Radulovic, Mandy Wan, Rahi Jahan, Gideon Lack
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s13063-017-1809-7) contains supplementary material, which is available to authorized users.

Abstract

Background

The evidence for systemic treatments for severe childhood eczema is limited and largely based on extrapolation of data from adult studies. Current therapies are often immunosuppressant and may be associated with both short- and long-term side effects. There is increasing in vitro and murine-model evidence for the role of IgE in the immunopathogenesis of atopic eczema. The aim of the study is to assess whether anti-IgE treatment (omalizumab) improves eczema, compared to placebo.

Methods/design

The Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT) is a randomised, double-blind, placebo-controlled study assessing the role of anti-IgE in the management of severe paediatric eczema. Children with severe atopic eczema, with an objective SCORing Atopic Dermatitis (SCORAD) score of over 40 will be recruited. These children are candidates for systemic therapy, have failed systemic therapy or have experienced side effects from systemic therapy. Sixty-two patients aged between 4 and 19 years will receive anti-IgE for 6 months. The primary outcome measure will be the validated eczema score, the objective SCORAD at 24 weeks. This study has 90% power to detect a 33% relative reduction in SCORAD between active and placebo groups, with 5% significance.

Discussion

IgE may have a role to play in eczema, particularly in childhood. This forms the basis for the hypothesis that anti-IgE may be an effective treatment in this patient population.
This will be the largest study to evaluate the efficacy of anti-IgE (omalizumab) versus placebo in children with severe eczema. The findings will help to clarify the role of anti-IgE as a potential treatment option in patients with severe childhood eczema.

Trial registration

European Clinical Trials Database (EudraCT) Number: 2010-020841-29. Assigned on 14 May 2010.
ISRCTN Registry, Identifier: ISRCTN15090567. Retrospectively assigned on 3 December 2014.
ClinicalTrials.gov, Identifier: NCT02300701. First received 21 November 2014.
Zusatzmaterial
Additional file 1: Figure S1. SPIRIT 2013 Checklist. (DOC 272 kb)
13063_2017_1809_MOESM1_ESM.doc
Additional file 2: Figure S2. Schedule of enrolment, interventions, and assessments. (DOC 68 kb)
13063_2017_1809_MOESM2_ESM.doc
Additional file 3: Figure S3. Gantt chart (timeline of the study, DOC). (DOCX 16 kb)
13063_2017_1809_MOESM3_ESM.docx
Additional file 4: Table S1. Primary and secondary outcomes (primary and secondary outcome measures of the study). (DOCX 20 kb)
13063_2017_1809_MOESM4_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Trials 1/2017 Zur Ausgabe